|
|
BART Study Suggests Problem with the Drug Trasylol
Contact us for a free legal consultation about your
Trasylol Lawsuit
BART Study May Get Suspended
On October 19, 2007, FDA was notified of the Data Safety Monitoring Board’s (DSMB) recommendation to stop patient enrollment in the aprotinin BART study. This early termination may signal problems with the drug. Aprtinin is marketed as Trasylol by Bayer, Inc.. Trasylol is used in blood conservation during surgery. The randomized trial in a cardiac surgery population (BART) study has preliminary findings suggesting that when compared to the antifibrinolytic drugs, epsilon-aminocaproic acid and tranexamic acid, aprotinin increases the risk of death.
The study had planned to follow 3,000 adult Canadian patients who were to have heart surgery and were at a high risk for bleeding.
The interim analyses showed that the 30-day mortality in the aprotinin group was stastically significant. The increased death rate in the aprotinin patients was observed in the study. Thus, the use of aprotinin for less serious bleeding cases could be a problem in terms of risk benefit.
Once additional data is collected, analyses will assess the findings from the BART study and determine if the drug should be pulled from the market.
The FDA anticipates re-evaluation of the overall risks and benefits of Trasylol. This re-evaluation may result in the drug being pulled from the market. An alternative would be to revise the labeling. Doctors are now on notice that the benefits of this drug may not outweigh the risks in many cases. Data is mounting against Trasylol, suggesting Trasylol administration increases the risk for death compared to other antifibrinolytic drugs.
Trasylol is used for prophylactic use to reduce perioperative blood loss in the course of coronary artery bypass graft (CABG) surgery.
Do you have a Trasylol lawsuit?
|
|